
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical Corp is projected to achieve Surgical Aesthetics revenue in the range of $43 million to $45 million, representing a year-over-year growth of 14% at the midpoint, supported by improved operational execution and rising demand trends. The company's management has raised its full-year revenue guidance to $50.5 million to $52.5 million, indicating confidence in continued growth driven by the Surgical Aesthetics segment. Additionally, the launch of the AYON product and the increasing adoption of GLP-1 weight-loss drugs, which lead to greater demand for skin tightening procedures, are expected to contribute positively to future revenue estimates, with FY2026 now projected at $58 million.
Bears say
Apyx Medical Corp faces challenges evidenced by a projected decline in OEM sales, expected to be around $7.5 million, down from prior guidance of $8.0 million, reflecting reduced sales volumes to key existing customers. The company has also encountered sustained downward pressure on its stock price since peaking at $17.40 in September 2021, influenced by the lingering effects of an FDA warning letter and rising competition from GLP-1 medications. Additionally, Apyx reported a decrease in cash and cash equivalents, falling from $29.3 million at the end of Q2 2025 to $25.1 million at the end of Q3 2025, indicating potential liquidity concerns amid ongoing volatility in its primary revenue-generating segment.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares